- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- September 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- March 2025
- 303 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- June 2024
- 140 Pages
Middle East, Africa
From €3678EUR$3,869USD£3,090GBP
- Report
- June 2018
- 315 Pages
Global
From €3326EUR$3,499USD£2,794GBP
- Report
- February 2022
- 193 Pages
Global
From €2495EUR$2,625USD£2,096GBP
€4991EUR$5,250USD£4,193GBP
- Report
- August 2023
- 117 Pages
Global
From €4278EUR$4,500USD£3,594GBP
In Silico Drug Discovery is a form of drug discovery that uses computer-based methods to identify potential drug candidates. This process involves the use of computer-aided drug design (CADD) and virtual screening techniques to identify compounds that have the desired pharmacological properties. In Silico Drug Discovery is used to reduce the time and cost associated with traditional drug discovery methods, such as high-throughput screening and medicinal chemistry. It also allows for the exploration of a much larger chemical space than is possible with traditional methods.
In Silico Drug Discovery is used by pharmaceutical and biotechnology companies to identify and develop new drugs. It is also used by academic and government research institutions to identify potential drug targets and to develop new drug candidates.
Some companies in the In Silico Drug Discovery market include Schrödinger, Inc., Accelrys, Inc., ChemAxon, Leadscope, Inc., and OpenEye Scientific Software, Inc. Show Less Read more